Novel agents that downregulate EGFR, HER2, and HER3 in parallel

EGFR, HER2, and HER3 contribute to the initiation and progression of human cancers, and are therapeutic targets for monoclonal antibodies and tyrosine kinase inhibitors. An important source of resistance to these agents arises from functional redundancy among EGFR, HER2, and HER3. EGFR family member...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Ferreira, Renan Barroso, Law, Mary Elizabeth, Jahn, Stephan Christopher, Davis, Bradley John, Heldermon, Coy Don, Reinhard, Mary, Castellano, Ronald Keith, Law, Brian Keith
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2015
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4496366/
https://ncbi.nlm.nih.gov/pubmed/25865227
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars